The use of betamethasone dipropionate/calcipotriol foam in proactive therapy of psoriasis — presentation of 2 cases
Abstract
Topical therapy of psoriasis is often chalenging in daily practice for both patients and treating physicians. Many patients experience severe recurrences shortly after cessation of therapy, usually within locations that were previously affected. Calcipotriol (CAL)/betamethasone dipropionate (BD) foam is, according to data from literature the most effective topical treatment option in psoriasis. The concept of proactive therapy has been known for years in relation to the topical treatment of atopic dermatitis with calcineurin inhibitors. Until now, strong scientific evidence for the efficacy of this approach in the treatment of resistant psoriatic lesions has been lacking. In clinical trials, the use of proactive therapy has been proven to be an effective and safe way to prevent relapse and maintain remission of the disease, which resulted in new indications in the Summary of Product Characteristics of BD/CAL foam. This paper presents 2 clinical cases of patients treated with proactive therapy with very good therapeutic effect, which proves that long-term proactive management of psoriasis using foam with BD/CAL is a convenient, effective and safe method of maintaining remission and preventing relapse of persistent psoriatic skin lesions.
Keywords: psoriasistopical therapyproactive therapybetamethasone dipropionatecalcipotriol
References
- Fouéré S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol. 2005; 19(Suppl 3): 2–6.
- Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011. JAMA Dermatol. 2013; 149(10): 1180–1185.
- Reich A, Adamski Z, Chodorowska G, et al. Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part I: Mild psoriasis. Dermatol Rev/Przegl Dermatol. 2018; 105(2): 225–243.
- Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017; 31(1): 119–126.
- Ito K, Koga M, Shibayama Y, et al. Proactive treatment with calcipotriol reduces recurrence of plaque psoriasis. J Dermatol. 2016; 43(4): 402–405.
- Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol. 2006; 154(6): 1155–1160.
- Luger TA, Cambazard F, Larsen FG, et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology. 2008; 217(4): 321–328.
- Saraceno R, Camplone G, D'Agostino M, et al. Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol® gel) in the treatment of scalp psoriasis: results from a study in 885 patients. J Dermatolog Treat. 2014; 25(1): 30–33.
- Augustin M, Mrowietz U, Bonnekoh B, et al. Topical long-term therapy of psoriasis with vitamin D₃ analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice. J Dtsch Dermatol Ges. 2014; 12(8): 667–682.
- Reich A, Adamski Z, Chodorowska G, et al. Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1. Dermatol Rev/Przegl Dermatol. 2020; 107(2): 92–108.
- Reich A, Adamski Z, Chodorowska G, et al. Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2. Dermatol Rev/Przegl Dermatol. 2020; 107(2): 110–137.
- Lebwohl M, Kircik L, Lacour JP. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). J Am Acad Dermatol. 2021; 84(5): 1269–1277.
